News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,455 Results
Type
Article (41910)
Company Profile (333)
Press Release (665212)
Section
Business (210166)
Career Advice (2080)
Deals (36582)
Drug Delivery (100)
Drug Development (82848)
Employer Resources (171)
FDA (16490)
Job Trends (15360)
News (355488)
Policy (33832)
Tag
Academia (2574)
Alliances (51185)
Alzheimer's disease (1275)
Approvals (16440)
Artificial intelligence (157)
Bankruptcy (362)
Best Places to Work (11715)
Biotechnology (215)
Breast cancer (191)
Cancer (1390)
Cardiovascular disease (116)
Career advice (1741)
Cell therapy (285)
Clinical research (66232)
Collaboration (495)
Compensation (263)
COVID-19 (2612)
C-suite (110)
Data (1400)
Diabetes (174)
Diagnostics (6255)
Earnings (86577)
Employer resources (149)
Events (112864)
Executive appointments (402)
FDA (17171)
Funding (432)
Gene therapy (206)
GLP-1 (631)
Government (4453)
Healthcare (18875)
Infectious disease (2704)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16616)
Job creations (4052)
Job search strategy (1488)
Layoffs (439)
Legal (8326)
Lung cancer (199)
Lymphoma (100)
Manufacturing (215)
Medical device (13297)
Medtech (13302)
Mergers & acquisitions (20117)
Metabolic disorders (470)
Neuroscience (1606)
NextGen Class of 2024 (6625)
Non-profit (4515)
Northern California (1701)
Obesity (268)
Opinion (207)
Patents (120)
People (58417)
Phase I (20511)
Phase II (29144)
Phase III (21855)
Pipeline (517)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (271)
Real estate (6240)
Regulatory (22510)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1468)
Startups (3712)
United States (15332)
Vaccines (582)
Weight loss (196)
Date
Today (31)
Last 7 days (590)
Last 30 days (2447)
Last 365 days (35752)
2024 (35554)
2023 (40630)
2022 (51797)
2021 (56330)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (202)
Asia (40138)
Australia (6423)
California (3836)
Canada (1455)
China (311)
Colorado (174)
Connecticut (179)
Europe (85476)
Florida (535)
Georgia (135)
Illinois (394)
Indiana (232)
Maryland (633)
Massachusetts (3007)
Michigan (174)
Minnesota (291)
New Jersey (1117)
New York (1086)
North Carolina (760)
Northern California (1701)
Ohio (146)
Pennsylvania (929)
South America (1157)
Southern California (1468)
Texas (557)
Utah (109)
Washington State (406)
707,455 Results for "citius pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
November 11, 2024
·
18 min read
Business
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended March 31, 2024.
May 14, 2024
·
13 min read
Press Releases
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
August 13, 2024
·
9 min read
Press Releases
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
August 5, 2024
·
8 min read
Press Releases
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
November 18, 2024
·
6 min read
Pharm Country
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
Citius Pharmaceuticals, Inc. today announced its participation in two upcoming investor conferences.
May 10, 2024
·
2 min read
Press Releases
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
November 19, 2024
·
5 min read
Press Releases
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
September 5, 2024
·
14 min read
Pharm Country
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. today announced that the Company has received $2.4 million in non-dilutive capital.
March 7, 2024
·
5 min read
Approvals
Citius Scores FDA Approval in Cutaneous T Cell Lymphoma
Citius Pharmaceuticals’ Lymphir is a reformulated version of denileukin diftitox—an FDA-approved cancer therapy—and the only treatment for cutaneous T cell lymphoma that targets the IL-2 receptor located on malignant T cells and Tregs.
August 9, 2024
·
2 min read
·
Tristan Manalac
1 of 70,746
Next
